• Dyne Therapeutics flagged new preclinical data for four Duchenne muscular dystrophy candidates, with results set for presentation on Sept. 25.
• The readouts are positioned to support advancement into IND-enabling studies, expanding the company’s exon-skipping franchise beyond exon 51.
• Data package points to meaningful exon skipping and dystrophin production in relevant models, supporting continued development across multiple mutation subsets.
• The programs use the same FORCE platform as zeleciment rostudirsen (DYNE-251), which remains under FDA review for exon 51 DMD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609030730PRIMZONEFULLFEED9820556) on September 03, 2026, and is solely responsible for the information contained therein.